Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hemostemix Inc (TSV:HEM)

0.0600 -0.0050 (-7.69%)
Streaming Delayed Price Updated: 3:57 PM EDT, Jul 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,911
Open 0.0650
Bid (Size) 0.0600 (2,880)
Ask (Size) 0.0650 (540)
Prev. Close 0.0650
Today's Range 0.0600 - 0.0650
52wk Range 0.0450 - 0.1400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Hemostemix Leadership Attending Abundance360 Summit
Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas... 
Via Newsfile
Topics Artificial Intelligence
News headline image
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem... 
Via Newsfile

Performance

YTD
-33.3%
-33.3%
1 Month
+9.1%
+9.1%
3 Month
N/A
N/A
6 Month
-33.3%
-33.3%
1 Year
-52.0%
-52.0%

More News

Read More
News headline image
Hemostemix Receives FDA Support for Its Basket Protocol Approach
Via Newsfile
News headline image
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Via Newsfile
News headline image
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Via Newsfile
News headline image
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
Via Newsfile
News headline image
Hemostemix Grants Stock Options
Via Newsfile
News headline image
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
Via Newsfile
News headline image
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum Agenda Announced for September 18th
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for March 13th
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
Via Newsfile
News headline image
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
Via Newsfile
News headline image
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
Via Newsfile
News headline image
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
Via Newsfile
Topics Intellectual Property
News headline image
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board
Via Newsfile
News headline image
Hemostemix Announces Its Presentation to the Emerging Growth Conference
Via Newsfile
Topics Economy Intellectual Property
News headline image
Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
Via Newsfile
News headline image
Hemostemix Announces Closing of $2,750,000
Via IssueWire
Topics Intellectual Property
News headline image
Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed
Via IssueWire
Topics Intellectual Property Lawsuit
News headline image
Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years
Via Newsfile
Topics Economy Intellectual Property
News headline image
Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results
Via Newsfile
Topics Economy Intellectual Property
News headline image
Peter Lacey Increases His Investment in Hemostemix Inc.
Via Newsfile
Topics Intellectual Property
News headline image
Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
Via Newsfile
Topics Economy Intellectual Property

Frequently Asked Questions

Is Hemostemix Inc publicly traded?
Yes, Hemostemix Inc is publicly traded.
What exchange does Hemostemix Inc trade on?
Hemostemix Inc trades on the Toronto Venture Stock Exchange
What is the ticker symbol for Hemostemix Inc?
The ticker symbol for Hemostemix Inc is HEM on the Toronto Venture Stock Exchange
What is the current price of Hemostemix Inc?
The current price of Hemostemix Inc is 0.0600
When was Hemostemix Inc last traded?
The last trade of Hemostemix Inc was at 07/22/26 03:57 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback